Raptor Pharmaceutical Corp (RPTP)

8.96
0.04 0.39
NASDAQ : Health Care
Prev Close 9.00
Open 8.98
Day Low/High 8.96 / 8.99
52 Wk Low/High 2.94 / 14.90
Volume 3.20M
Avg Volume 1.94M
Exchange NASDAQ
Shares Outstanding 85.31M
Market Cap 765.20M
EPS -0.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Arbor and Purdue Seen as Likely Bidders for DepoMed

Arbor and Purdue Seen as Likely Bidders for DepoMed

The pharmaceutical company is reportedly up for sale after being dogged by Starboard Value for months, and could go for up to $41 million.

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information

INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Raptor...

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding The Fairness Of The Sale Of Raptor Pharmaceutical Corp. To Horizon Pharma Plc For $9.00 Per Share

INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Regarding The Fairness Of The Sale Of Raptor Pharmaceutical Corp. To Horizon Pharma Plc For $9.00 Per Share

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Raptor Pharmaceutical Corp.

More Rare Disease Dealmaking to Follow Horizon's Raptor Deal

More Rare Disease Dealmaking to Follow Horizon's Raptor Deal

The buyer's CEO said it will look at both large acquisitions and Phase 2 and pre-approved assets in the wake of the $800 million purchase of the maker of Procysbi.

RPTP Crosses Above Average Analyst Target

RPTP Crosses Above Average Analyst Target

In recent trading, shares of Raptor Pharmaceuticals Corp. have crossed above the average analyst 12-month target price of $8.40, changing hands for $8.98/share.

Fed Dove Brainard Pushes Stocks Into Rally Mode

Fed Dove Brainard Pushes Stocks Into Rally Mode

Relief floods Wall Street on Monday after a number of Federal Reserve speakers take a dovish turn following increasingly hawkish rhetoric coming out of the central bank.

Closing Bell: Fed's Brainard Cautions 'Prudence'; U.S. Stocks Soar

Closing Bell: Fed's Brainard Cautions 'Prudence'; U.S. Stocks Soar

Relief flooded Wall Street after a number of Fed speakers took a dovish turn following increasingly hawkish rhetoric.

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Investors To Contact The Firm For Additional Information

SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Raptor...

7 Stocks Trading on Big Volume -- and What to Do With Them Now

7 Stocks Trading on Big Volume -- and What to Do With Them Now

Here's a technical look at how to trade some of the most active stocks on the market right now.

Stocks Extend Gains as Fed's Brainard Urges 'Prudence' With Rates; Oil Gains

Stocks Extend Gains as Fed's Brainard Urges 'Prudence' With Rates; Oil Gains

Stocks rise Monday after Federal Reserve Gov. Lael Brainard urges 'prudence' in raising rates.

RAPTOR PHARMACEUTICAL CORP. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Horizon Pharma Plc

RAPTOR PHARMACEUTICAL CORP. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe And Powers Taylor LLP Investigate Sale To Horizon Pharma Plc

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Raptor...

Raptor Pharmaceutical (RPTP) Stock Soars on $800 Million Horizon Pharma Deal

Raptor Pharmaceutical (RPTP) Stock Soars on $800 Million Horizon Pharma Deal

Horizon Pharma (HZNP) is buying Raptor Pharmaceutical (RPTP) in a deal that's expected to improve its rare disease business.

Stocks Rise but Come Off Highs Amid Rate Hike Worries

Stocks Rise but Come Off Highs Amid Rate Hike Worries

Stocks pare gains on Monday as worries over how soon the Federal Reserve might hike interest rates keeps markets wary.

Stock Futures Pare Losses After Fed's Lockhart Stays Coy on Interest Rates

Stock Futures Pare Losses After Fed's Lockhart Stays Coy on Interest Rates

Stock futures moved sharply lower on Monday morning, extending Friday's selloff, as worries continued over how soon the Federal Reserve might hike interest rates.

Horizon Pharma Swoops In on Raptor With $800 Million Bid

Horizon Pharma Swoops In on Raptor With $800 Million Bid

Horizon says the $800 million offer will bolster its rare disease business and its operations outside the U.S..

Raptor Pharmaceuticals (RPTP) Stock Surges on Potential Retrophin Deal

Raptor Pharmaceuticals (RPTP) Stock Surges on Potential Retrophin Deal

Retrophin (RTRX) is said to be exploring a possible purchase of Raptor Pharmaceuticals (RPTP).

Raptor Pharmaceutical (RPTP) Is Strong On High Volume Today

Raptor Pharmaceutical (RPTP) Is Strong On High Volume Today

Trade-Ideas LLC identified Raptor Pharmaceutical (RPTP) as a strong on high relative volume candidate

First Week of February 2017 Options Trading For Raptor Pharmaceuticals (RPTP)

First Week of February 2017 Options Trading For Raptor Pharmaceuticals (RPTP)

Investors in Raptor Pharmaceuticals Corp. saw new options begin trading this week, for the February 2017 expiration.